Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay
Not yet recruiting
- Conditions
- T-Cell Lymphoproliferative Disorder
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Invivoscribe, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT06876571
- Locations
- ๐บ๐ธ
Invivoscribe, Inc., San Diego, California, United States
๐ฉ๐ชLabPMM GmbH, Hallbergmoos, Germany
๐ฏ๐ตLabPMM GK, Kawasaki-shi, Kanagawa, Japan
The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research
Recruiting
- Conditions
- Hematologic Diseases
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Invivoscribe, Inc.
- Target Recruit Count
- 2000
- Registration Number
- NCT06222164
- Locations
- ๐บ๐ธ
LabPMM, San Diego, California, United States
Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx IGH Assay
Completed
- Conditions
- B-Cell Lymphoproliferative Disorder
- Interventions
- Diagnostic Test: IdentiClone Dx IGH (IC IGH Dx) Assay
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Invivoscribe, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT06112301
- Locations
- ๐บ๐ธ
Invivoscribe, Inc., San Diego, California, United States
๐ฉ๐ชLabPMM GmbH, Hallbergmoos, Germany
๐ฏ๐ตLabPMM GK, Kawasaki-shi, Kanagawa, Japan
The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines
- Conditions
- SARS-CoV-2
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Invivoscribe, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT04391400
ยฉ Copyright 2025. All Rights Reserved by MedPath